Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
40 patients were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.ClinicalTrials.gov Identifier: NCT03796364. [CLINICALTRIALS.GOV IDENTIFIER] NCT03796364.
[BACKGROUND] Radiation pneumonitis (RP) is a common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC).
- p-value P = .038
- p-value P = .048
- 95% CI 0.27-1.16
- HR 0.56
APA
Chen G, Zhu J, et al. (2025). Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.. The oncologist, 30(11). https://doi.org/10.1093/oncolo/oyaf318
MLA
Chen G, et al.. "Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.." The oncologist, vol. 30, no. 11, 2025.
PMID
41014160 ↗
Abstract 한글 요약
[BACKGROUND] Radiation pneumonitis (RP) is a common adverse event related to thoracic radiotherapy in patients with non-small cell lung cancer (NSCLC). The treatment of RP needs to be improved.
[METHODS] NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.
[RESULTS] A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs 1.47 months, P = .048). The RP mortality rate was 5% and 35% in the Rh-endostatin group and control group, respectively (P = .044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25% vs 45%, P = .185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 and 6.0 months, respectively (hazard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.40-2.23, P = .910). The median overall survival was 16.0 and 7.7 months in two groups, respectively (HR: 0.56, 95%CI: 0.27-1.16, P = .119). There was no significant difference between the two groups in adverse events.
[CONCLUSION] This prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients.
[DISCUSSION] This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.ClinicalTrials.gov Identifier: NCT03796364.
[CLINICALTRIALS.GOV IDENTIFIER] NCT03796364.
[METHODS] NSCLC patients with grade 2 or higher RP were enrolled and randomly assigned into 2 groups: recombinant human endostatin (Rh-endostatin) group (Rh-endostatin + glucocorticoid) and control group (glucocorticoid only). The primary endpoint was RP relapse rate.
[RESULTS] A total of 40 patients were included. The relapse rate of RP was significantly lower in Rh-endostatin group (15% vs 45%, P = .038). Though the remission rate of RP was similar in the two groups, the combined therapy significantly reduced the interval from RP treatment to RP remission (0.92 vs 1.47 months, P = .048). The RP mortality rate was 5% and 35% in the Rh-endostatin group and control group, respectively (P = .044). The incidence of pulmonary fibrosis was numerically lower in Rh-endostatin group (25% vs 45%, P = .185). The circulating lymphocyte levels in Rh-endostatin group significantly increased after treatment, when compared to the control group. The median progression-free survival was 7.8 and 6.0 months, respectively (hazard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.40-2.23, P = .910). The median overall survival was 16.0 and 7.7 months in two groups, respectively (HR: 0.56, 95%CI: 0.27-1.16, P = .119). There was no significant difference between the two groups in adverse events.
[CONCLUSION] This prospective randomized study provides evidence that the combination of Rh-endostatin and glucocorticoids can reduce RP relapse rates and promote remission without increasing adverse events in advanced NSCLC patients.
[DISCUSSION] This Discussion can take one of two forms: 350 words and two salient graphics, such as a table, schema, waterfall plot, image or graph; or 450 words with a single salient graphic. This discussion is part of the Abstract and as such needs to be distinct from the extended Discussion at the end of the paper. Citation of references should be done in the extended Discussion at the end of the CTR; references (up to 5) should be cited in the Author Summary only if absolutely necessary.ClinicalTrials.gov Identifier: NCT03796364.
[CLINICALTRIALS.GOV IDENTIFIER] NCT03796364.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
- Prediction of non-sentinel lymph node metastasis using the clinical features of thrombin time under the status of 1-2 positive sentinel lymph node of breast cancer.
- Text-Guided Multi-stage Cross-perception Network for Medical Image Segmentation.
- ALDH1L1 reverses CD8 T cell exhaustion in the oral squamous cell carcinoma microenvironment by reprogramming L-glutamate metabolism.
- Efficacy and safety of tislelizumab as neoadjuvant treatment in patients with stage II-III microsatellite instability-high/mismatch repair-deficient colorectal cancer: a single-arm, multicenter, open-label, prospective, phase II study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.